Nektar Therapeutics to Participate in Two Investor Conferences in November

Nektar Therapeutics (Nasdaq: NKTR) announced that management will participate in two investor conferences in London on November 17–18, 2026.

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) announced that management will participate in two investor conferences in London on November 17–18, 2026.

The UBS Global Biopharma Conference fireside chat is scheduled for November 17 at 11:20–11:50 a.m. GMT; the Jefferies Global Healthcare Conference chat follows November 18 at 8:00–8:25 a.m. GMT. Both include one-on-one meetings. Live and archived webcasts will be available on Nektar’s investor website, with replays available for 30 days.

Key Terms

regulatory t cell stimulator, bispecific, tumor necrosis factor receptor type ii, hematopoietic colony stimulating factor

4 terms

regulatory t cell stimulator medical

"a novel, first-in-class regulatory T cell stimulator"

An agent (drug, biologic, cell therapy or vaccine) designed to increase the number or suppressive activity of regulatory T cells (Tregs), a subset of immune cells that limit inflammation and prevent immune attacks on the body's own tissues. It can work by expanding Tregs, enhancing their ability to suppress other immune cells, or directing antigen-specific Tregs to a target tissue; this is distinct from broad immunosuppression because the effect may be targeted to Treg biology or particular antigens rather than indiscriminately blocking immune function.

bispecific medical

"preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

tumor necrosis factor receptor type ii medical

"tumor necrosis factor receptor type II (TNFR2) antibody"

A cell-surface protein that binds the inflammatory signaling molecule tumor necrosis factor (TNF); known as TNF receptor type II or TNFR2, it sits on the membranes of certain immune and non-immune cells and transmits signals inside the cell after TNF binding. TNFR2 typically activates pathways that promote cell survival, proliferation, or immune regulation (for example via NF-κB signaling) and differs from TNF receptor type I (TNFR1), which more often triggers cell-death or broad inflammatory responses. The receptor’s effects depend on which cells express it, whether it is engaged by soluble or membrane-bound TNF, and on the cellular context and co‑existing signals.

hematopoietic colony stimulating factor medical

"a modified hematopoietic colony stimulating factor (CSF) protein"

A hematopoietic colony-stimulating factor is a naturally occurring or manufactured protein that stimulates the growth, survival and differentiation of blood-forming progenitor cells in the bone marrow so they form colonies of specific blood cell types (for example neutrophils or red cells). These factors act by binding receptors on hematopoietic progenitor cells and promoting proliferation and maturation; they affect precursor cells rather than directly increasing numbers of fully mature blood cells. They may be produced by the body or given as recombinant drugs to accelerate recovery of particular blood cell lines after chemotherapy, bone marrow suppression or certain medical procedures, and their use can be associated with predictable effects on blood counts and known side effects related to marrow stimulation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences.

• UBS Global Biopharma Conference
  • Format: Fireside Chat and 1x1 meetings
  • Fireside Chat Date: Tuesday, November 17, 2026
  • Fireside Chat Time: 11:20 – 11:50 a.m. GMT
  • Location: London, UK

• Jefferies Global Healthcare Conference
  • Format: Fireside Chat and 1x1 meetings
  • Fireside Chat Date: Wednesday, November 18, 2026
  • Fireside Chat Time: 8:00 – 8:25 a.m. GMT
  • Location: London, UK

The live and archived webcasts will be accessible from the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events and replays will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com 

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-november-302936871.html

SOURCE Nektar Therapeutics